September 2026

Join WhatsApp Channel 

Regulatory Affairs Courses
Work as GMP Compliance Trainee Officer at Lupin
1 September 2026

Work as GMP Compliance Trainee Officer at Lupin

To prepare and review documents like Risk Assessment protocols for product change over, Cleaning/Process Validation protocols, Master Formula Records, Batch Manufacturing Records. Review technology transfer documents for Mammalian and Microbial products with coordination with R&D, QC and RA.
Zydus Reports Positive Phase II(b) Results for Saroglitazar Mg in MASH
1 September 2026
Zydus Reports Positive Phase II(b) Results for Saroglitazar Mg in MASH

Zydus Lifesciences has announced positive topline results from its global EVIDENCES-X™ Phase II(b) clinical trial evaluating Saroglitazar Magnesium in patients with Metabolic dysfunction-Associated Steatohepatitis (MASH) and fibrosis. The company said the study successfully achieved its primary endpoint, marking an important milestone in its ongoing MASH development programme.

₹5,000 Crore PRIP Scheme Opens Second Funding Round for Pharma and MedTech Innovation
1 September 2026
₹5,000 Crore PRIP Scheme Opens Second Funding Round for Pharma and MedTech Innovation
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme, creating fresh funding opportunities for startups, MSMEs and pharmaceutical and MedTech companies working on high-impact innovations.
Trump Administration Adds Nine Pharma Companies to U.S. Drug Price-Cut Deal; Sun Pharma, Teva Among Signatories
1 September 2026
Trump Administration Adds Nine Pharma Companies to U.S. Drug Price-Cut Deal; Sun Pharma, Teva Among Signatories

The Trump administration has announced agreements with nine additional pharmaceutical manufacturers aimed at reducing prescription drug prices in the United States under its Most-Favored-Nation (MFN) pricing initiative.

The latest agreements bring the total number of pharmaceutical manufacturers participating in the administration's MFN arrangements to 26 companies, covering approximately 89% of the branded drug market, according to a White House fact sheet released on August 31.